Refeyn

<p>This company was started by Philip Kukura to commercialize <a class="wikilink" href="/iscat/">iSCAT</a> devices. I am not sure about their internal structure, but it has been active since 2018. </p> <p>In Nov 2020 they got a <strong>30MU$</strong> round. </p> <p>Their devices are sold for 170k€, installation and 1-day training are 2300U$, and they have a range of consumables (like clean coverslips). </p> <p>As far as I understand, their goal since the inception of the company is the traditional Oxford path: get acquired ASAP. After a 30M round, I see this a bit less likely in the short term. In order to grow to a ~300M valuation, they'll have to achieve sales of around 200 devices a year and show no stagnation. </p> <p>That may be the deal with <a class="wikilink" href="/illumion/">Illumion</a>, opening new business lines without sacrificing their own capital and brand in the bio sector.</p>